Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

NYX-2925 is a novel NMDA receptor modulator that induces rapid and long-lasting analgesia in rat models of neuropathic pain.

Ghoreishi-Haack N, Priebe JM, Aguado JD, Colechio EM, Burgdorf JS, Bowers MS, Cearley CN, Khan MA, Moskal JR.

J Pharmacol Exp Ther. 2018 Jul 9. pii: jpet.118.249409. doi: 10.1124/jpet.118.249409. [Epub ahead of print]

2.

The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.

Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, Khan MA.

Curr Neuropharmacol. 2017;15(1):47-56. Review.

3.

GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.

Rajagopal L, Burgdorf JS, Moskal JR, Meltzer HY.

Behav Brain Res. 2016 Feb 15;299:105-10. doi: 10.1016/j.bbr.2015.10.060. Epub 2015 Nov 26.

4.

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.

Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD.

Expert Opin Investig Drugs. 2014 Feb;23(2):243-54. doi: 10.1517/13543784.2014.852536. Epub 2013 Nov 20. Review.

5.

Regional changes in gene expression after limbic kindling.

Corcoran ME, Kroes RA, Burgdorf JS, Moskal JR.

Cell Mol Neurobiol. 2011 Aug;31(6):819-34. doi: 10.1007/s10571-011-9672-7. Epub 2011 Mar 19.

PMID:
21424270

Supplemental Content

Loading ...
Support Center